Floatz logo

8 assets in Malignant Endocrine Neoplasm

Therapeutic assets addressing Malignant Endocrine Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)P2B (60)
Pembrolizumab
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)P2B (60)
Fludarabine
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Tcr Transduced T-Cells
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Clostridium Novyi-Nt
Malignant Endocrine Neoplasm
M.D. Anderson Cancer CenterP1CC (43)
Doxycycline
Malignant Endocrine Neoplasm
M.D. Anderson Cancer CenterP1CC (43)
Olaparib
Malignant Endocrine Neoplasm
M.D. Anderson Cancer CenterP1CC (43)
Selumetinib
Malignant Endocrine Neoplasm
M.D. Anderson Cancer CenterP1CC (43)